	US 12,440,538 B2
	Treatment for ocular fibrosis
Dimitrios Karamichos, Carrollton, TX (US)
Assigned to UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH, Fort Worth, TX (US)
Appl. No. 18/853,789
Filed by UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH, Fort Worth, TX (US)
PCT Filed Apr. 7, 2023, PCT No. PCT/US2023/017816 § 371(c)(1), (2) Date Oct. 3, 2024, PCT Pub. No. WO2023/196555, PCT Pub. Date Oct. 12, 2023.
Claims priority of provisional application 63/328,826, filed on Apr. 8, 2022.
Prior Publication US 2025/0222067 A1, Jul. 10, 2025
Int. Cl. A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61P 27/02 (2006.01)

CPC A61K 38/1709 (2013.01) [A61K 9/0048 (2013.01); A61P 27/02 (2018.01)]

15 Claims

1. A method of treating ocular fibrosis of the eye in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of a prolactin-Inducible Protein (PIP) that inhibits or reverses the ocular fibrosis.